Team:San Andres
| Home | Team | Project | Statistics | Enzymes | Parts | Metodology | Results | Future Projections |
|
Home
The
celiac disease affects 1 in 265 people worldwide
and 15% of population in Chile. This is an irreversible autoimmune
disease in
which due to the presence of genes HLA DQ2 or HLA-DQ8 in those
affected, the
consumption of foods containing gluten (all foods derived from wheat,
barley,
rye, etc.) cause an inflammation in the small intestine causing
multiple
effects in the organism (diarrhea, constipation, poor absorption, among
others)
significantly affecting their quality of life.
Whereas
the majority of the world food contains
gluten, we propose a treatment for those who can’t eat gluten, and can
do so
without problems. In detail, our project involves a system able to
degrade
gluten via the enzyme KumaMax and report the operation simultaneously
with a
red fluorescent protein. The foregoing, works in a genetically modified
E. coli
bacteria. With this project, in the long run, we hope to improve the
quality of
life of all those reported with celiac disease.
